TrialThe lancet. HIV2023

Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.

Magdalena E Sobieszczyk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.